Amylyx Pharmaceuticals, Inc. (AMLX)
Automate Your Wheel Strategy on AMLX
With Tiblio's Option Bot, you can configure your own wheel strategy including AMLX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AMLX
- Rev/Share -0.0148
- Book/Share 2.3503
- PB 3.1442
- Debt/Equity 0.0069
- CurrentRatio 12.0535
- ROIC -1.0205
- MktCap 658752655.0
- FreeCF/Share -2.4165
- PFCF -3.1811
- PE -2.8937
- Debt/Assets 0.0063
- DivYield 0
- ROE -1.0628
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AMLX | Goldman | -- | Buy | -- | $10 | July 10, 2025 |
| Initiation | AMLX | Guggenheim | -- | Buy | -- | $17 | June 24, 2025 |
| Initiation | AMLX | Citigroup | -- | Buy | -- | $12 | June 17, 2025 |
| Initiation | AMLX | TD Cowen | -- | Buy | -- | -- | May 30, 2025 |
| Upgrade | AMLX | Mizuho | Neutral | Outperform | -- | $7 | April 7, 2025 |
| Upgrade | AMLX | BofA Securities | Neutral | Buy | $4.2 | $10 | Oct. 23, 2024 |
News
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.
Read More
About Amylyx Pharmaceuticals, Inc. (AMLX)
- IPO Date 2022-01-07
- Website https://amylyx.com
- Industry Biotechnology
- CEO Joshua B. Cohen
- Employees 123